|
1
|
Berry DA, Cronin KA, Plevritis SK, Fryback
DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and
Feuer EJ: Cancer Intervention and Surveillance Modeling Network
(CISNET) Collaborators: Effect of screening and adjuvant therapy on
mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnston SR: New strategies in estrogen
receptor-positive breast cancer. Clinical Cancer Res. 16:1979–1987.
2010. View Article : Google Scholar
|
|
3
|
Lo S and Johnston SR: Novel systemic
therapies for breast cancer. Surg Oncol. 12:277–287. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gutierrez MC, Detre S, Johnston S, Mohsin
SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M:
Molecular changes in tamoxifen-resistant breast cancer:
Relationship between estrogen receptor, HER-2, and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SH, Chung MA, Quddus MR, Steinhoff MM
and Cady B: The effect of neoadjuvant chemotherapy on estrogen and
progesterone receptor expression and hormone receptor status in
breast cancer. Am J Surg. 186:348–350. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang X, Phillips DL, Ferguson AT, Nelson
WG, Herman JG and Davidson NE: Synergistic activation of functional
estrogen receptor (ER)-alpha by DNA methyltransferase and histone
deacetylase inhibition in human ER-alpha-negative breast cancer
cells. Cancer Res. 61:7025–7029. 2001.PubMed/NCBI
|
|
7
|
Kuukasjärvi T, Kononen J, Helin H, Holli K
and Isola J: Loss of estrogen receptor in recurrent breast cancer
is associated with poor response to endocrine therapy. J Clin
Oncol. 14:2584–2589. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Won HY, Lee JY, Shin DH, Park JH, Nam JS,
Kim HC and Kong G: Loss of Mel-18 enhances breast cancer stem cell
activity and tumorigenicity through activating Notch signaling
mediated by the Wnt/TCF pathway. FASEB J. 26:5002–5013. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gruvberger S, Ringnér M, Chen Y, Panavally
S, Saal LH, Borg A, Fernö M, Peterson C and Meltzer PS: Estrogen
receptor status in breast cancer is associated with remarkably
distinct gene expression patterns. Cancer Res. 61:5979–5984.
2001.PubMed/NCBI
|
|
10
|
Niemeier LA, Dabbs DJ, Beriwal S, Striebel
JM and Bhargava R: Androgen receptor in breast cancer: Expression
in estrogen receptor-positive tumors and in estrogen
receptor-negative tumors with apocrine differentiation. Mod Pathol.
23:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al Saleh S, Al Mulla F and Luqmani YA:
Estrogen receptor silencing induces epithelial to mesenchymal
transition in human breast cancer cells. PLoS One. 6:e206102011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luqmani YA, Al Azmi A, Al Bader M, Abraham
G and El Zawahri M: Modification of gene expression induced by
siRNA targeting of estrogen receptor alpha in MCF7 human breast
cancer cells. Int J Oncol. 34:231–242. 2009.PubMed/NCBI
|
|
13
|
Ma X, Cai Y, He D, Zou C, Zhang P, Lo CY,
Xu Z, Chan FL, Yu S, Chen Y, et al: Transient receptor potential
channel TRPC5 is essential for P-glycoprotein induction in
drug-resistant cancer cells. Proc Natl Acad Sci USA.
109:16282–16287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma X, Chen Z, Hua D, He D, Wang L, Zhang
P, Wang J, Cai Y, Gao C, Zhang X, et al: Essential role for
TrpC5-containing extracellular vesicles in breast cancer with
chemotherapeutic resistance. Proc Natl Acad Sci USA. 111:6389–6394.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He DX, Gu XT, Jiang L, Jin J and Ma X: A
methylation-based regulatory network for microRNA 320a in
chemoresistant breast cancer. Mol Pharmacol. 86:536–547. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He DX, Gu XT, Li YR, Jiang L, Jin J and Ma
X: Methylation-regulated miRNA-149 modulates chemoresistance by
targeting NDST1 in human breast cancer. FEBS J. 281:4718–4730.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang L, He D, Yang D, Chen Z, Pan Q, Mao
A, Cai Y, Li X, Xing H, Shi M, et al: MiR-489 regulates
chemoresistance in breast cancer via epithelial mesenchymal
transition pathway. FEBS Lett. 588:200920152014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang F, Reeves K, Han X, Fairchild C,
Platero S, Wong TW, Lee F, Shaw P and Clark E: Identification of
candidate molecular markers predicting sensitivity in solid tumors
to dasatinib: Rationale for patient selection. Cancer Res.
67:2226–2238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or Paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bonnefoi H, Potti A, Delorenzi M, Mauriac
L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot
E, et al: Retraction - Validation of gene signatures that predict
the response of breast cancer to neoadjuvant chemotherapy: A
substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol.
12:1162011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Esserman LJ, Berry DA, Cheang MC, Yau C,
Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg
ME, et al: I-SPY 1 TRIAL Investigators: Chemotherapy response and
recurrence-free survival in neoadjuvant breast cancer depends on
biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB
150007/150012; ACRIN 6657). Breast Cancer Res Treat. 132:1049–1062.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buffa FM, Camps C, Winchester L, Snell CE,
Gee HE, Sheldon H, Taylor M, Harris AL and Ragoussis J:
microRNA-associated progression pathways and potential therapeutic
targets identified by integrated mRNA and microRNA expression
profiling in breast cancer. Cancer Res. 71:5635–5645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao
CK, Chang KJ and Chuang EY: Molecular characteristics and
metastasis predictor genes of triple-negative breast cancer: A
clinical study of triple-negative breast carcinomas. PLoS One.
7:e458312012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tofigh A, Suderman M, Paquet ER,
Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S,
Lesurf R, et al: The prognostic ease and difficulty of invasive
breast carcinoma. Cell Rep. 9:129–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Desmedt C, Piette F, Loi S, Wang Y,
Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y,
d'Assignies MS, et al: TRANSBIG Consortium: Strong time dependence
of the 76-gene prognostic signature for node-negative breast cancer
patients in the TRANSBIG multicenter independent validation series.
Clin Cancer Res. 13:3207–3214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang DY, Done SJ, Mc Cready DR and Leong
WL: Validation of the prognostic gene portfolio, ClinicoMolecular
Triad Classification, using an independent prospective breast
cancer cohort and external patient populations. Breast Cancer Res.
16:R712014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He DX, Xia YD, Gu XT, Jin J and Ma X: A
transcription/translation-based gene signature predicts resistance
to chemotherapy in breast cancer. J Pharm Biomed Anal. 102:500–508.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hastie T, Sleeper L and Tibshirani R:
Flexible covariate effects in the proportional hazards model.
Breast Cancer Res Treat. 22:241–250. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lachenbruch PA: Discriminant diagnostics.
Biometrics. 53:1284–1292. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He DX, Xia YD, Gu XT, Jin J and Ma X: A
20-gene signature in predicting the chemoresistance of breast
cancer to taxane-based chemotherapy. Mol Biosyst. 10:3111–3119.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang
Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et
al: A pathway-based classification of human breast cancer. Proc
Natl Acad Sci U S A. 107:6994–6999. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tönjes M, Barbus S, Park YJ, Wang W,
Schlotter M, Lindroth AM, Pleier SV, Bai AHC, Karra D, Piro RM, et
al: BCAT1 promotes cell proliferation through amino acid catabolism
in gliomas carrying wild-type IDH1. Nat Med. 19:901–908. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou W, Feng X, Ren C, Jiang X, Liu W,
Huang W, Liu Z, Li Z, Zeng L, Wang L, et al: Over-expression of
BCAT1, a c-Myc target gene, induces cell proliferation, migration
and invasion in nasopharyngeal carcinoma. Mol Cancer. 12:532013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Magnani L, Ballantyne EB, Zhang X and
Lupien M: PBX1 genomic pioneer function drives ERα signaling
underlying progression in breast cancer. PLoS Genet.
7:e10023682011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Emery LA, Tripathi A, King C, Kavanah M,
Mendez J, Stone MD, de las Morenas A, Sebastiani P and Rosenberg
CL: Early dysregulation of cell adhesion and extracellular matrix
pathways in breast cancer progression. Am J Pathol. 175:1292–1302.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schumacker PT: Reactive oxygen species in
cancer: a dance with the devil. Cancer Cell. 27:156–157. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang H, Zhang Q, He J and Lu W: Regulation
of calcium signaling in lung cancer. J Thorac Dis. 2:52–56.
2010.PubMed/NCBI
|
|
38
|
Monteith GR, McAndrew D, Faddy HM and
Roberts-Thomson SJ: Calcium and cancer: Targeting Ca2+
transport. Nat Rev Cancer. 7:519–530. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sommer S and Fuqua SA: Estrogen receptor
and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Isakoff SJ: Triple-negative breast cancer:
Role of specific chemotherapy agents. Cancer J. 16:53–61. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bell DR, Gerlach JH, Kartner N, Buick RN
and Ling V: Detection of P-glycoprotein in ovarian cancer: A
molecular marker associated with multidrug resistance. J Clin
Oncol. 3:311–315. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li X, Li JP, Yuan HY, Gao X, Qu XJ, Xu WF
and Tang W: Recent advances in P-glycoprotein-mediated multidrug
resistance reversal mechanisms. Methods Find Exp Clin Pharmacol.
29:607–617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Townsend DM and Tew KD: The role of
glutathione-S-transferase in anti-cancer drug resistance. Oncogene.
22:7369–7375. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
